Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 113INDUSTRY 61NIH 5OTHER_GOV 4NETWORK 3

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4Pathologic Complete Response 2

Interventions

Tamoxifen 10Docetaxel 8Trastuzumab 7Paclitaxel 6Letrozole 6Gemcitabine 6Exercise 6Control Groups 6exemestane 5Indocyanine Green 5Cyclophosphamide 5Carboplatin 5Anastrozole 5pertuzumab 4dalpiciclib 4Vinorelbine 4Doxorubicin 4Capecitabine 4pyrotinib 3Surgical Procedures, Operative 3Standard of Care 3Radiotherapy 3Radiation 3Mammography 3Fulvestrant 3Cisplatin 3ferumoxides 2Zoledronic Acid 2Tablets 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER_GOV × Breast Neoplasms × pertuzumab × Clear all
NCT07057427 2025-07-09

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Henan Cancer Hospital

Phase 3 Recruiting
812 enrolled
Breast

Breast Neoplasms

NCT07047755 2025-07-02

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Not yet recruiting
48 enrolled
Breast

Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡